Hormone IUD to preserve fertility in early uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or younger
- You strongly want to keep the possibility of future pregnancy (fertility preservation)
- Your biopsy shows a specific diagnosis: grade 1 endometrial cancer with progesterone receptor positivity, or atypical endometrial hyperplasia
- Imaging shows disease is limited to the uterus lining (for cancer; stage 1A by MRI)
- Your blood test CA125/199 is normal (for cancer), and a procedure may be needed to rule out spread to ovaries/other sites
- You can take the study treatments safely and agree to regular follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This trial studies whether removing an early, hormone-responsive uterine growth using a procedure through the cervix can keep fertility possible. It is for people under 40 with a specific low-risk uterine biopsy and MRI findings who have already tried hormone treatment.
This study tests whether combining ultrasound with tissue samples can better monitor women with early-stage endometrial cancer or precancer who choose fertility-sparing treatment instead of hysterectomy. It may help preserve your ability to have children while closely tracking the disease.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.